FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325287262> ?p ?o ?g. }

• W2325287262 endingPage "E8" @default.
• W2325287262 startingPage "E8" @default.
• W2325287262 abstract "The objective of this analysis was to determine the extent of antibody response to influenza and pneumococcal vaccination in adult patients with rheumatoid arthritis (RA) receiving certolizumab pegol (CZP) or placebo (PBO) and consider the application of these data to adult patients with Crohn’s disease (CD). Patients in this 6-week, single-blind, PBO-controlled, phase IV trial (NCT00993668) were randomized 1:1 and stratified by concomitant methotrexate to receive CZP 400 mg or PBO at Weeks 0, 2, and 4. All patients received commercially available 23-valent pneumococcal and 2009-10 trivalent subvirion influenza virus vaccines at Week 2, prior to dosing with CZP. The co-primary endpoints (assessed independently) were the percentage of patients in the per protocol set (PPS, included only those patients without protective titers at baseline) with a satisfactory humoral response, defined as a ≥2-fold titer increase in ≥3 of 6 pneumococcal antigens (6B, 9V, 14, 18C, 19F, and 23F), and a ≥4-fold increase for each of 3 influenza antigens (H1N1 [nonpandemic], H3N2, and B) at Week 6. Differences in proportions between groups were presented with a 95% confidence interval (CI). Of 224 randomized patients (CZP=110, PBO=114), 217 (96.0%) completed the study. Baseline demographics were similar between groups; 65.5% (72/110) of CZP and 68.4% (78/114) of PBO patients had concomitant methotrexate (mean dose, 16.6 mg/week). In the PPS, following pneumococcal vaccination 53.3% of CZP patients (48/90) and 62.2% (56/90) of PBO patients achieved humoral response at Week 6 (-8.9; 95%CI: -23.3, 5.5); following influenza vaccination, 54.0% (47/87) of CZP patients and 61.9% (52/84) of PBO patients achieved humoral response (-7.9; 95% CI: -22.7; 6.9). There was a >2-fold increase from baseline to Week 6 in titers in both treatment groups for each of the antigens tested in all patients including those with protective titers at baseline (full analysis set, FAS). Following vaccination, 62.6% (67/107) of CZP and 65.5% (72/110) of PBO patients and 71.0% (76/107) of CZP and 77.1% (84/109) of PBO patients in the FAS developed protective pneumococcal and influenza antibody titers, respectively. Responses to pneumococcal and influenza antigens were reduced in both groups who received concomitant methotrexate vs those who did not (CZP vs PBO: pneumococcal antigens, with methotrexate = 45.2% [28/62] vs 49.2% [30/61], without methotrexate = 71.4% [20/28] vs 89.7% [26/29]; influenza antigens, with concomitant methotrexate = 47.4% [27/57] vs 50.9% [29/57], without concomitant methotrexate = 66.7% [20/30] vs 85.2% [23/27]). Incidence of adverse events was comparable across groups; most events were mild to moderate in intensity. There was 1 death in the CZP group (unrelated to study drug) and none in the PBO group. Humoral responses to pneumococcal and influenza vaccines were comparable in patients receiving treatment with CZP and PBO. Vaccine responses were reduced in both treatment groups with concomitant methotrexate. These results indicate that patients receiving CZP can be effectively immunized with pneumococcal and influenza vaccines. Although these data were not collected in CD patients, they should be considered when CD patients require immunization with pneumococcal and influenza vaccines." @default.
• W2325287262 created "2016-06-24" @default.
• W2325287262 creator A5009369964 @default.
• W2325287262 creator A5017764759 @default.
• W2325287262 creator A5059168844 @default.
• W2325287262 creator A5066986646 @default.
• W2325287262 creator A5082669130 @default.
• W2325287262 date "2014-02-01" @default.
• W2325287262 modified "2023-09-27" @default.
• W2325287262 title "P-146 Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients Receiving Certolizumab Pegol" @default.
• W2325287262 doi "https://doi.org/10.1097/01.mib.0000442972.72852.6e" @default.
• W2325287262 hasPublicationYear "2014" @default.
• W2325287262 type Work @default.
• W2325287262 sameAs 2325287262 @default.
• W2325287262 citedByCount "0" @default.
• W2325287262 crossrefType "journal-article" @default.
• W2325287262 hasAuthorship W2325287262A5009369964 @default.
• W2325287262 hasAuthorship W2325287262A5017764759 @default.
• W2325287262 hasAuthorship W2325287262A5059168844 @default.
• W2325287262 hasAuthorship W2325287262A5066986646 @default.
• W2325287262 hasAuthorship W2325287262A5082669130 @default.
• W2325287262 hasBestOaLocation W23252872621 @default.
• W2325287262 hasConcept C126322002 @default.
• W2325287262 hasConcept C159654299 @default.
• W2325287262 hasConcept C203014093 @default.
• W2325287262 hasConcept C22070199 @default.
• W2325287262 hasConcept C2776215756 @default.
• W2325287262 hasConcept C2777288759 @default.
• W2325287262 hasConcept C2777575956 @default.
• W2325287262 hasConcept C2779384505 @default.
• W2325287262 hasConcept C2780132546 @default.
• W2325287262 hasConcept C2781059491 @default.
• W2325287262 hasConcept C32611913 @default.
• W2325287262 hasConcept C71924100 @default.
• W2325287262 hasConcept C90924648 @default.
• W2325287262 hasConceptScore W2325287262C126322002 @default.
• W2325287262 hasConceptScore W2325287262C159654299 @default.
• W2325287262 hasConceptScore W2325287262C203014093 @default.
• W2325287262 hasConceptScore W2325287262C22070199 @default.
• W2325287262 hasConceptScore W2325287262C2776215756 @default.
• W2325287262 hasConceptScore W2325287262C2777288759 @default.
• W2325287262 hasConceptScore W2325287262C2777575956 @default.
• W2325287262 hasConceptScore W2325287262C2779384505 @default.
• W2325287262 hasConceptScore W2325287262C2780132546 @default.
• W2325287262 hasConceptScore W2325287262C2781059491 @default.
• W2325287262 hasConceptScore W2325287262C32611913 @default.
• W2325287262 hasConceptScore W2325287262C71924100 @default.
• W2325287262 hasConceptScore W2325287262C90924648 @default.
• W2325287262 hasIssue "2" @default.
• W2325287262 hasLocation W23252872621 @default.
• W2325287262 hasOpenAccess W2325287262 @default.
• W2325287262 hasPrimaryLocation W23252872621 @default.
• W2325287262 hasRelatedWork W1251505628 @default.
• W2325287262 hasRelatedWork W1973582357 @default.
• W2325287262 hasRelatedWork W1977601919 @default.
• W2325287262 hasRelatedWork W2021678191 @default.
• W2325287262 hasRelatedWork W2028691273 @default.
• W2325287262 hasRelatedWork W2138814539 @default.
• W2325287262 hasRelatedWork W3085122866 @default.
• W2325287262 hasRelatedWork W384163677 @default.
• W2325287262 hasRelatedWork W4256594459 @default.
• W2325287262 hasRelatedWork W4312127714 @default.
• W2325287262 hasVolume "20" @default.
• W2325287262 isParatext "false" @default.
• W2325287262 isRetracted "false" @default.
• W2325287262 magId "2325287262" @default.
• W2325287262 workType "article" @default.